Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications: DLCO/VA% is More important than predicted postoperative %DLCO?
Takeda
Shin-ichi
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002248:Carbon Monoxide / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D008297:Male; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D011013:Pneumonectomy / Q000009:adverse effects* / Q000379:methods; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D011237:Predictive Value of Tests; D011653:Pulmonary Diffusing Capacity; D012129:Respiratory Function Tests; D012680:Sensitivity and Specificity; D014797:Vital Capacity
D002248:Carbon Monoxide